Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
25 February 2023 - 08:33AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF
FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February, 2023
Commission File Number 000-29962
Kazia Therapeutics Limited
(Translation of registrants name into English)
Three
International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☑ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
On February 24, 2023, Kazia Therapeutics Limited (the Company) issued an ASX release titled Results of
EGM in connection with its Extraordinary General Meeting that was held on February 24, 2023 at 3:00 p.m. (Sydney time).
The
Company hereby incorporates by reference the information contained herein into the Companys registration statement on Form F-3 (File No. 333-259224).
EXHIBIT LIST
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
Kazia Therapeutics Limited (Registrant) |
|
/s/ Karen Krumeich |
Karen Krumeich |
Chief Financial Officer |
|
Date: February 24, 2023 |
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Mar 2023 to Mar 2024